Stites and Harbison's Biotechnology/Life Sciences Law Group includes highly experienced and dedicated attorneys focused on intellectual property protection of all aspects of biotechnology and life sciences. These include genetic engineering, immunology, monoclonal antibodies, medical devices, diagnostics, therapeutics, genetic markers, and pharmaceuticals.

The Intellectual Property (IP) members of the Biotechnology/Life Sciences Law Group have extensive backgrounds in biotechnology and related fields, including work in research laboratories, experience with Patent Examination for the USPTO, and advanced degrees, and/or technical experience in fields such as microbiology and immunology, biology, and pharmacology and cell biophysics.

Our Biotechnology/Life Sciences Technology attorneys represent a full range of clients in the biotechnological arts, ranging from major companies and universities through a number of smaller start-up businesses.

In addition to patent prosecution, the Biotechnology/Life Sciences group counsels clients on all matters relating to domestic and international intellectual property issues. This includes issues relating to infringement, validity, and freedom to operate. Our group also has deep experience in litigation, and has handled cases involving biotechnological inventions in both federal and state courts.

Stites & Harbison distinguishes itself by having ongoing relationships with intellectual property firms throughout the world. This gives our clients access to highly skilled international intellectual property counsel wherever and whenever needed.

In addition to offices in the major Southeastern cities of Atlanta, Lexington, Louisville, and Nashville, our strategically located office in Alexandria, Virginia, allows Stites & Harbison attorneys to have in-person visits with Patent Examiners at the United States Patent & Trademark Office to discuss cases and advance our clients' positions.

Examples of recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include the following:

• 11,326,138 - Cell culture device and methods of use thereof
• 11,325,901 - Prostaglandin E synthase inhibitors and methods for utilizing the same
• 11,324,743 - Treatment for the non alcoholic steatohepatitis and fibrosis
  
• 11,319,304 - Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
• 11,318,137 - Quinazoline compounds as modulators of Ras signaling
• 11,311,600 - Methods for treating obesity
• 11,311,563 - Method and composition for preventing and treating viral infections
• 11,306,069 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands
• 11,305,039 - Polymeric vascular grafts which induce neovascularization with mild to minimal inflammation and promotion of fibrovascular tissue
• 11,286,464 - Viral vaccines and methods of forming the same
• 11,285,133 - 2- or 3-imidazolines as carbapenemases inhibitors
• 11,273,210 - Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
• 11,266,614 - Oral formulations of belinostat
• 11,261,166 - Lipophilic macrocyclic ligands, complexes thereof, and uses of same
• 11,248,038 - Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
• 11,242,342 - Isoquinoline amine compounds as mGlu
• 11,236,303 - CD34.sup.+CD41.sup.DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
• 11,230,714 - Gene silencing kills emerald ash borer, an exotic, invasive tree-killing insect
• 11,225,481 - Xanthine derivative inhibitors of BET proteins
• 11,224,609 - Mithramycin derivatives having increased selectivity and anti-cancer activity
• 11,220,528 - Compositions and methods for treating pulmonary hypertension
• 11,219,623 - Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis

Biotechnology/Life Sciences is part of Stites & Harbison's larger, Intellectual Property and Technology (IPT) group, which includes more than 20 attorneys – many of whom are Registered U.S. Patent Attorneys – with experience spanning all technical disciplines. Our IPT group uses a team approach to provide clients with comprehensive intellectual property services. Our attorneys practice throughout the nation and the world in the areas of patents, trademarks, copyrights, trade secrets, licensing, computer software, e-commerce and intellectual property litigation.